country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-163981

Copy Link Print Information

ABCB1-IN-2

ABCB1-IN-2 (compound 16q) is a functional inhibitor that can directly bind to the ABCB1 protein and stabilize its structure without affecting the expression and subcellular localization of ABCB1. ABCB1-IN-2 can increase the sensitivity of MCF-7/ADR cells to paclitaxel (PTX), increase the accumulation of PTX, and prevent the accumulation and excretion of luciferin Rh123 mediated by ABCB1. ABCB1-IN-2, as an ABCB1-mediated multidrug resistance (MDR) reversal agent, shows a strong ability to reverse MDR.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₂₉H₂₉N₃O₆S
Masse moléculaire:547.62

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

ABCB1-IN-2 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

ABCB1^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	>20 μM Compound: 16q	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 39151276]
MCF7	IC₅₀	2.65 nM Compound: 16q	Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM) Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)	[PMID: 39151276]
MCF7	IC₅₀	2.96 nM Compound: 16q	Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM) Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)	[PMID: 39151276]
NCI/ADR-RES	IC₅₀	>20 μM Compound: 16q	Antiproliferative activity against human MCF7ADR cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7ADR cells incubated for 72 hrs by MTT assay	[PMID: 39151276]
NCI/ADR-RES	IC₅₀	0.027 μM Compound: 16q	Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM) Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)	[PMID: 39151276]
NCI/ADR-RES	IC₅₀	10.07 nM Compound: 16q	Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM) Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)	[PMID: 39151276]

Chemical Information

Masse moléculaire 547.62
Formule C₂₉H₂₉N₃O₆S
SMILES

COC1=C(OC)C(OC)=CC(C2=C(C3=CC(OC)=C(OC)C(OC)=C3)C(C)=NC4=CC(C5=CC=CS5)=NN24)=C1
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock